-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
On February 23, Convalife announced that it has reached a clinical cooperation with Hutchison Pharmaceuticals to evaluate the high selection of PARP inhibitors Mefurpiride and Hutchison Pharmaceuticals with "best-in-class" potential for approval for listing The safety and tolerability of Fruquintinib combined with the treatment of solid tumors.
Mefuparib (CVL218) is a polyadenosine diphosphate ribose polymerase (PARP) inhibitor.
Fruquintinib Capsules (Ayute) is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3.
Note: The original text has been deleted